Cargando…

Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck

BACKGROUND: Treatment options for advanced head and neck adenoid cystic carcinoma (AdCC) are limited. Prostate-Specific Membrane Antigen (PSMA), a transmembrane protein that is known for its use in diagnostics and targeted therapy in prostate cancer, is also expressed by AdCC. This study aimed to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein Nulent, Thomas J. W., Valstar, Matthijs H., Smit, Laura A., Smeele, Ludwig E., Zuithoff, Nicolaas P. A., de Keizer, Bart, de Bree, Remco, van Es, Robert J. J., Willems, Stefan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275445/
https://www.ncbi.nlm.nih.gov/pubmed/32503460
http://dx.doi.org/10.1186/s12885-020-06847-9
_version_ 1783542784857210880
author Klein Nulent, Thomas J. W.
Valstar, Matthijs H.
Smit, Laura A.
Smeele, Ludwig E.
Zuithoff, Nicolaas P. A.
de Keizer, Bart
de Bree, Remco
van Es, Robert J. J.
Willems, Stefan M.
author_facet Klein Nulent, Thomas J. W.
Valstar, Matthijs H.
Smit, Laura A.
Smeele, Ludwig E.
Zuithoff, Nicolaas P. A.
de Keizer, Bart
de Bree, Remco
van Es, Robert J. J.
Willems, Stefan M.
author_sort Klein Nulent, Thomas J. W.
collection PubMed
description BACKGROUND: Treatment options for advanced head and neck adenoid cystic carcinoma (AdCC) are limited. Prostate-Specific Membrane Antigen (PSMA), a transmembrane protein that is known for its use in diagnostics and targeted therapy in prostate cancer, is also expressed by AdCC. This study aimed to analyse PSMA expression in a large cohort of primary, recurrent and metastasized AdCC of the head and neck. METHODS: One hundred ten consecutive patients with histologically confirmed AdCC in the period 1990–2017 were included. An analysis was made of clinical details, revised pathology and semiquantitative immunohistochemical expression of PSMA on tissue microarray and whole slides. Associations of PSMA expression with clinicopathological parameters were explored and survival was analysed by multivariate Cox-proportional Hazard analysis. RESULTS: PSMA expression was present in 94% of the 110 primary tumours, with a median of 31% positive cells (IQR 15–60%). Primary tumours (n = 18) that recurred (n = 15) and/or had metastases (n = 10) demonstrated 40, 60 and 23% expression respectively. Expression was not independently related to increased pathological stage, tumour grade, and the occurrence of locoregional recurrence or metastasis. After dichotomization, only primary tumour PSMA expression ≤10% appeared to be associated with reduced 10-years recurrence-free survival (HR 3.0, 95% CI 1.1–8.5, p = .04). CONCLUSIONS: PSMA is highly expressed in primary, recurrent and metastatic AdCC of the salivary and seromucous glands. PSMA expression has no value in predicting clinical behaviour of AdCC although low expression may indicate a reduced recurrence-free survival. This study provides supporting results to consider using PSMA as target for imaging and therapy when other diagnostic and palliative treatment options fail.
format Online
Article
Text
id pubmed-7275445
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72754452020-06-08 Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck Klein Nulent, Thomas J. W. Valstar, Matthijs H. Smit, Laura A. Smeele, Ludwig E. Zuithoff, Nicolaas P. A. de Keizer, Bart de Bree, Remco van Es, Robert J. J. Willems, Stefan M. BMC Cancer Research Article BACKGROUND: Treatment options for advanced head and neck adenoid cystic carcinoma (AdCC) are limited. Prostate-Specific Membrane Antigen (PSMA), a transmembrane protein that is known for its use in diagnostics and targeted therapy in prostate cancer, is also expressed by AdCC. This study aimed to analyse PSMA expression in a large cohort of primary, recurrent and metastasized AdCC of the head and neck. METHODS: One hundred ten consecutive patients with histologically confirmed AdCC in the period 1990–2017 were included. An analysis was made of clinical details, revised pathology and semiquantitative immunohistochemical expression of PSMA on tissue microarray and whole slides. Associations of PSMA expression with clinicopathological parameters were explored and survival was analysed by multivariate Cox-proportional Hazard analysis. RESULTS: PSMA expression was present in 94% of the 110 primary tumours, with a median of 31% positive cells (IQR 15–60%). Primary tumours (n = 18) that recurred (n = 15) and/or had metastases (n = 10) demonstrated 40, 60 and 23% expression respectively. Expression was not independently related to increased pathological stage, tumour grade, and the occurrence of locoregional recurrence or metastasis. After dichotomization, only primary tumour PSMA expression ≤10% appeared to be associated with reduced 10-years recurrence-free survival (HR 3.0, 95% CI 1.1–8.5, p = .04). CONCLUSIONS: PSMA is highly expressed in primary, recurrent and metastatic AdCC of the salivary and seromucous glands. PSMA expression has no value in predicting clinical behaviour of AdCC although low expression may indicate a reduced recurrence-free survival. This study provides supporting results to consider using PSMA as target for imaging and therapy when other diagnostic and palliative treatment options fail. BioMed Central 2020-06-05 /pmc/articles/PMC7275445/ /pubmed/32503460 http://dx.doi.org/10.1186/s12885-020-06847-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Klein Nulent, Thomas J. W.
Valstar, Matthijs H.
Smit, Laura A.
Smeele, Ludwig E.
Zuithoff, Nicolaas P. A.
de Keizer, Bart
de Bree, Remco
van Es, Robert J. J.
Willems, Stefan M.
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
title Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
title_full Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
title_fullStr Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
title_full_unstemmed Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
title_short Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
title_sort prostate-specific membrane antigen (psma) expression in adenoid cystic carcinoma of the head and neck
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275445/
https://www.ncbi.nlm.nih.gov/pubmed/32503460
http://dx.doi.org/10.1186/s12885-020-06847-9
work_keys_str_mv AT kleinnulentthomasjw prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT valstarmatthijsh prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT smitlauraa prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT smeeleludwige prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT zuithoffnicolaaspa prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT dekeizerbart prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT debreeremco prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT vanesrobertjj prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck
AT willemsstefanm prostatespecificmembraneantigenpsmaexpressioninadenoidcysticcarcinomaoftheheadandneck